Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome

Genes and Immunity

Volumn 14, Issue 4, 2013, Pages 244-248

  Kalincik, T ^a,b,c,f   Guttmann, C R G ^d   Krasensky, J ^a   Vaneckova, M ^a   Lelkova, P ^a   Tyblova, M ^a   Seidl, Z ^a   De Jager, P L ^b,e   Havrdova, E ^a   Horakova, D ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

genotype; MRI; multiple sclerosis; phenotype; prognosis; susceptibility

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CHEMOKINE RECEPTOR CXCR4; GLATIRAMER; HLA B ANTIGEN; HLA DRB1 ANTIGEN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 12P35; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; REFADOR; UNCLASSIFIED DRUG;

ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CORPUS CALLOSUM; DEMYELINATING DISEASE; DISABILITY; DISEASE COURSE; FOLLOW UP; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BRAIN; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878902187     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2013.17     Document Type: Article

References (30)

1. IMSGC. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
2. Alcina A, Abad-Grau Mdel M, Fedetz M, Izquierdo G, Lucas M, Fernandez O et al. Multiple sclerosis risk variant HLA-DRB1 1501 associates with high expression of DRB1 gene in different human populations. PLoS One 2012; 7: e29819.
3. IMSGC. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219.
4. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT et al. Metaanalysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.
5. De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009; 8: 1111-1119.
6. Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA et al. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One 2010; 5: e10003.
7. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F et al. Genomewide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18: 767-778.
8. IMSGC. Genome-wide association study of severity in multiple sclerosis. Genes Immun 2011; 12: 615-625.
9. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009; 132(Pt 1): 250-259.
10. Kelly MA, Cavan DA, Penny MA, Mijovic CH, Jenkins D, Morrissey S et al. The influence of HLA-DR and-DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. Human Immunol 1993; 37: 185-191. (Pubitemid 23286694)
11. Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L et al. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome medicine 2011; 3: 3.
12. IMSGC. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immun 2010; 11: 397-405.
13. Weatherby SJ, Thomson W, Pepper L, Donn R, Worthington J, Mann CL et al. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol 2001; 248: 304-310. (Pubitemid 32323869)
14. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 184-187.
15. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000; 178: 132-135.
16. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000; 48: 211-219. (Pubitemid 30617040)
17. Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E et al. The impact of HLA-A and-DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007; 14: 835-840. (Pubitemid 47108189)
18. Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, Moore SB et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998; 51: 742-747. (Pubitemid 28449253)
19. Harding K, Ingram G, Cossburn M, Hirst C, Pickersgill T, Ben-Shlomo Y et al. Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis. Neurosci Lett 2012; 526: 15-19.
20. Hauser SL, Oksenberg JR, Lincoln R, Garovoy J, Beck RW, Cole SR et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurology 2000; 54: 1859-1861. (Pubitemid 30428420)
21. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Human Genet 2003; 72: 710-716. (Pubitemid 36255969)
22. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
23. Shulman J, Chibnik L, Aubin C, Schneider J, Bennett D, De Jager P. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. PLoS One 2010; 5: e11244-e11244.
24. Xia Z, Chibnik LB, Glanz BI, Liguori M, Shulman JM, Tran D et al. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One 2010; 5: e14169.
25. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496. (Pubitemid 39410414)
26. Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, Havrdova E et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: A Longitudinal Cohort Study. PLoS One 2012; 7: e50101.
27. Ticha V, Kalincik T, Havrdova E. Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis. Neurol Res 2012; 34: 923-930.
28. Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg 2012; 114: 940-946.
29. Vaneckova M, Kalincik T, Krasensky J, Horakova D, Havrdova E, Hrebikova T et al. Corpus callosum atrophy-a simple predictor of multiple sclerosis progression: A Longitudinal 9-Year Study. Eur Neurol 2012; 68: 23-27.
30. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.